Q2 EPS Estimate for Vanda Pharmaceuticals Reduced by Analyst

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a report issued on Monday, May 11th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($0.52) per share for the quarter, down from their previous forecast of ($0.51). HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($2.19) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.98) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at $0.01 EPS and FY2027 earnings at ($0.36) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%.The firm had revenue of $51.72 million during the quarter, compared to analyst estimates of $54.98 million.

A number of other equities analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Monday, April 20th. Zacks Research downgraded shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 18th. Truist Financial started coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, March 5th. They set a “buy” rating and a $18.00 price objective for the company. Finally, Wall Street Zen lowered shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.30.

Vanda Pharmaceuticals Stock Performance

VNDA stock opened at $6.42 on Wednesday. The stock’s 50 day simple moving average is $7.43 and its 200 day simple moving average is $6.82. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $9.94. The firm has a market cap of $386.07 million, a P/E ratio of -1.59 and a beta of 0.65. The company has a current ratio of 2.16, a quick ratio of 2.15 and a debt-to-equity ratio of 0.01.

Insider Activity

In other Vanda Pharmaceuticals news, CFO Kevin Patrick Moran sold 42,442 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $8.27, for a total transaction of $350,995.34. Following the transaction, the chief financial officer owned 411,380 shares of the company’s stock, valued at approximately $3,402,112.60. This trade represents a 9.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Joakim Wijkstrom sold 30,800 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $8.27, for a total transaction of $254,716.00. Following the sale, the chief marketing officer owned 333,469 shares in the company, valued at $2,757,788.63. This trade represents a 8.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 314,342 shares of company stock worth $2,583,985 over the last ninety days. 8.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VNDA. Torren Management LLC bought a new stake in Vanda Pharmaceuticals during the fourth quarter worth approximately $25,000. Russell Investments Group Ltd. increased its position in shares of Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,328 shares during the period. Caitong International Asset Management Co. Ltd increased its position in shares of Vanda Pharmaceuticals by 3,010.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 10,055 shares during the period. Jain Global LLC bought a new stake in shares of Vanda Pharmaceuticals in the 4th quarter worth $94,000. Finally, Quarry LP acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at $53,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.